Deadline: 31-Jan-2026
The Pfizer-Astellas Alliance offers grants to support independent medical education initiatives for healthcare professionals on locally advanced/metastatic urothelial cancer (la/mUC) and muscle-invasive bladder cancer (MIBC).
Grants ranging from $10,000 to $200,000 aim to bridge educational gaps, promote best practices, and accelerate adoption of emerging therapies in clinical practice globally.
The Pfizer-Astellas Alliance, a collaboration between Astellas Pharma and Pfizer, has launched a grant opportunity to fund independent medical education initiatives that address current knowledge gaps in the treatment of locally advanced/metastatic urothelial cancer (la/mUC) and muscle-invasive bladder cancer (MIBC).
The grants aim to help healthcare professionals integrate emerging treatment approaches, such as Enfortumab Vedotin-based combinations, into routine clinical practice while accounting for regional treatment differences and guideline adoption.
Purpose of the Grant
The initiative seeks to enhance professional education by:
-
Addressing educational gaps in la/mUC and MIBC management
-
Promoting timely adoption of emerging clinical data
-
Supporting best practices in patient care and treatment decision-making
-
Enhancing awareness of regional variations in treatment access and sequencing
Geographic Scope
Applications are welcome from a broad range of regions, with priority given to:
Applications providing educational content in multiple languages are encouraged. Due to regulatory restrictions, applications from Japan and South Korea are not eligible.
Funding Details
-
Grant range: $10,000 – $200,000 per project
-
Total estimated budget: $750,000
-
Eligible costs include:
-
Direct project costs
-
Institutional overhead (capped at 22%)
-
Indirect costs
-
The funding structure allows organizations to fully support educational initiatives and ensure high-quality delivery.
Eligible Applicants
Eligible organizations include:
-
Medical, nursing, allied health, and pharmacy professional schools
-
Healthcare institutions and hospitals
-
Professional organizations and medical societies
-
Accredited medical education companies
Eligibility notes:
-
Individual physicians or independent physician groups cannot apply
-
Collaborative projects must designate a primary lead organization
-
All participating institutions must have meaningful roles in the project
Project Lead Requirements
Applicants must be:
-
Project or program leads, or authorized designees
-
Employed or contracted by the requesting organization
-
Authorized to submit on behalf of an organization legally able to receive funding from Astellas Pharma Global Development
Projects offering continuing education credits must be submitted by an accredited organization.
Project Focus Areas
Funded projects should address:
-
Knowledge gaps in la/mUC and MIBC management
-
Emerging treatment options and therapeutic combinations
-
Regional variations in access, sequencing norms, and guideline adherence
-
Education strategies for multidisciplinary healthcare professionals
How to Apply
-
Confirm eligibility for both organization and project lead
-
Prepare a detailed project proposal including:
-
Learning objectives
-
Target audience and reach
-
Proposed educational methods and format
-
Expected outcomes and impact on clinical practice
-
Budget with breakdown of direct, indirect, and overhead costs
-
-
Submit the application according to grant guidelines
-
Await review and potential funding decision
Why This Grant Matters
The grant provides a platform for healthcare organizations to:
-
Advance professional education in urothelial cancer and MIBC
-
Promote evidence-based clinical practices
-
Support rapid adoption of new therapies and treatment guidelines
-
Improve patient care outcomes through targeted educational interventions
Tips for a Strong Application
-
Clearly define learning objectives and measurable outcomes
-
Align content with current treatment gaps and emerging therapies
-
Demonstrate reach across relevant healthcare professional groups
-
Include a robust plan for multilingual or region-specific content if applicable
-
Ensure clear budget justification and compliance with funding guidelines
Common Mistakes to Avoid
-
Submitting as an individual or physician group instead of an organization
-
Failing to designate a primary lead in collaborative proposals
-
Proposing activities outside la/mUC or MIBC education scope
-
Omitting accreditation requirements if continuing education credits are offered
-
Providing incomplete budget or financial details
Frequently Asked Questions (FAQ)
What types of projects are eligible?
Independent medical education initiatives addressing la/mUC and MIBC knowledge gaps.
Who can submit an application?
Eligible organizations include schools, healthcare institutions, professional organizations, and accredited medical education companies.
Are individual healthcare professionals eligible to apply?
No. Applications must be submitted by eligible organizations.
What is the funding range per project?
$10,000 to $200,000 per individual project.
Can collaborative projects involve multiple organizations?
Yes, but all entities must have meaningful roles, with one primary lead organization.
Are applications from Japan and South Korea accepted?
No, due to local laws and regulations.
Can grants cover overhead and indirect costs?
Yes, institutional overhead is capped at 22%, and indirect costs are allowable.
Conclusion
The Pfizer-Astellas Alliance Medical Education Grant provides a vital opportunity for healthcare organizations to enhance professional knowledge, address treatment gaps in la/mUC and MIBC, and accelerate the adoption of innovative therapies in clinical practice worldwide. By supporting high-quality, evidence-based educational initiatives, this grant fosters improved patient care and promotes best practices across diverse healthcare settings.
For more information, visit Pfizer.